WITHDRAWN: Is TGF-β1 And SMAD-7 Expression At Diagnosis Predictive Of Treatment Response In Patients With Low-Risk Myelodysplastic Syndrome?

Summary: Important Notice: This scientific article has been officially withdrawn by the publisher and authors.

Originally, the paper aimed to investigate whether specific genetic markers (TGF-β1 and SMAD-7) could help doctors predict how patients with low-risk Myelodysplastic Syndrome (a group of cancers in which immature blood cells in the bone marrow do not mature) would respond to treatment. However, due to reasons specified by the publisher (often involving data integrity, errors, or ethical concerns), the findings are no longer considered valid. The scientific community and patients should not rely on the information previously contained in this study.